In this study we demonstrate an effective inhibition of FB2 on Ba/F3 P210 cell lines in vitro, and provide mechanistic evidences that the inhibition is mediated through reducing the phosphorylation of Bcr Abl and Src kinases. Further studies is going to be done to analyze the expressions of cell cycle proteins and cyclin dependent kinase and verify this end up in future. Furthermore, FB2 triggers G0/G1 cell period arrest, cell growth is inhibited by potently AZD5363. More over, our current findings in vivo mixed with the earlier in the day results observe that FB2 has important anticancer activity in mouse xenograft models which were inoculated with K562, K562/G5. 0, and Ba/F3 p210 cell lines. These data supply the framework for clinical trials with FB2 in Ph+ CML and imtinib resisitant CML. Angiogenesis is seen as a the formation of new capillaries from pre existing vessels. This event is really a prerequisite for both physiological and pathological processes as previously noted. The poor prognosis of some diseases like cancer has been shown to correlate with the increase in angiogenesis. An extreme vascularization may also contribute to other pathological phenomena such as atherosclerosis plaque formation and Infectious causes of cancer persistent in?ammation. Angiogenesis is a process induced by angiogenic facets. Vascular endothelial growth factor and basic?broblast growth factor were the 2 most well known angiogenic factors. Recently, monocyte released cytokine oncostatin M was identi?ed as yet another strong angiogenesis stimulating factor that could play a major role in the devel-opment and complication of atherosclerosis. These factors contribute in two critical steps of angiogenesis, i. e. endothelial cell proliferation and migration. Besides these cytokines, different serine proteases such MAPK pathway cancer as urokinase typ-e plasminogen activator and plasmin as well as matrix metalloproteinases may also be implicated in the cell migration process. Angiogenesis may be inhibited by anti angiogenic facets. Different anti angiogenic elements to date identi?ed like thrombospondin, endostatin and angiostatin are all protein fragments. These improve the issue for the fee purchase and pharmaceutical production for longterm therapeutically government required by anti angiogenic therapy. Some small anti angiogenic elements like marimastat show significant area e?ects within the clinical analysis. So, the devel-opment of new anti angiogenic elements appears emergent for both anti atherosclerosis remedies and anti cancer. The 3 hydroxy 3 methyl glutaryl coenzyme A reductase inhibitor, cerivastatin, is originally proven to inhibit cholesterol biosynthesis. Recent studies showed that cerivastatin has pleiotropic e?ects such as the inhibition of smooth muscle cell migration and proliferation.